|
1
|
Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline.
|
Arch Neurol
|
2002
|
4.60
|
|
2
|
Resting state functional connectivity of the striatum in Parkinson's disease.
|
Brain
|
2012
|
2.53
|
|
3
|
The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study.
|
BMC Med
|
2008
|
2.10
|
|
4
|
The impact of litigation on neurologic research.
|
Neurology
|
2006
|
2.03
|
|
5
|
Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study.
|
Arch Neurol
|
2006
|
1.94
|
|
6
|
Mutations in CIZ1 cause adult onset primary cervical dystonia.
|
Ann Neurol
|
2012
|
1.82
|
|
7
|
The focal dystonias: current views and challenges for future research.
|
Mov Disord
|
2013
|
1.62
|
|
8
|
Selective defect of in vivo glycolysis in early Huntington's disease striatum.
|
Proc Natl Acad Sci U S A
|
2007
|
1.57
|
|
9
|
Task-specific dystonias: a review.
|
Ann N Y Acad Sci
|
2008
|
1.54
|
|
10
|
Principal component analysis of PiB distribution in Parkinson and Alzheimer diseases.
|
Neurology
|
2013
|
1.53
|
|
11
|
Cervical carotid and circle of willis arterial anatomy of macaque monkeys: a comparative anatomy study.
|
Anat Rec (Hoboken)
|
2009
|
1.47
|
|
12
|
Oromandibular and lingual dystonia associated with spinocerebellar ataxia type 8.
|
Mov Disord
|
2012
|
1.44
|
|
13
|
Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: the GenePD study.
|
Mov Disord
|
2008
|
1.41
|
|
14
|
Relative risk of spread of symptoms among the focal onset primary dystonias.
|
Mov Disord
|
2006
|
1.36
|
|
15
|
Research priorities in spasmodic dysphonia.
|
Otolaryngol Head Neck Surg
|
2008
|
1.31
|
|
16
|
Amyloid imaging of Lewy body-associated disorders.
|
Mov Disord
|
2010
|
1.27
|
|
17
|
Predictors of survival in patients with Parkinson disease.
|
Arch Neurol
|
2012
|
1.27
|
|
18
|
Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia.
|
Arch Neurol
|
2012
|
1.26
|
|
19
|
Mapping Go-No-Go performance within the subthalamic nucleus region.
|
Brain
|
2010
|
1.26
|
|
20
|
Effect of stimulation frequency on tremor suppression in essential tremor.
|
Mov Disord
|
2004
|
1.26
|
|
21
|
Increased risk of parkinsonism associated with welding exposure.
|
Neurotoxicology
|
2012
|
1.23
|
|
22
|
A possible substrate for dopamine-related changes in mood and behavior: prefrontal and limbic effects of a D3-preferring dopamine agonist.
|
Proc Natl Acad Sci U S A
|
2002
|
1.22
|
|
23
|
Parkinson disease is not associated with C9ORF72 repeat expansions.
|
Neurobiol Aging
|
2012
|
1.22
|
|
24
|
Basal ganglia intensity indices and diffusion weighted imaging in manganese-exposed welders.
|
Occup Environ Med
|
2012
|
1.17
|
|
25
|
Neurologist-associated reduction in PD-related hospitalizations and health care expenditures.
|
Neurology
|
2012
|
1.17
|
|
26
|
High-throughput mutational analysis of TOR1A in primary dystonia.
|
BMC Med Genet
|
2009
|
1.14
|
|
27
|
[18F]FDOPA PET and clinical features in parkinsonism due to manganism.
|
Mov Disord
|
2005
|
1.11
|
|
28
|
A comparison of D2 receptor specific binding in obese and normal-weight individuals using PET with (N-[(11)C]methyl)benperidol.
|
Synapse
|
2013
|
1.07
|
|
29
|
[3H]4-(dimethylamino)-N-(4-(4-(2-methoxyphenyl)piperazin-1-yl) butyl)benzamide: a selective radioligand for dopamine D(3) receptors. II. Quantitative analysis of dopamine D(3) and D(2) receptor density ratio in the caudate-putamen.
|
Synapse
|
2010
|
1.07
|
|
30
|
Gait and balance in essential tremor: variable effects of bilateral thalamic stimulation.
|
Mov Disord
|
2009
|
1.06
|
|
31
|
Dopaminergic modulation of response inhibition: an fMRI study.
|
Brain Res Cogn Brain Res
|
2004
|
1.06
|
|
32
|
[(3)H]4-(Dimethylamino)-N-[4-(4-(2-methoxyphenyl)piperazin- 1-yl)butyl]benzamide, a selective radioligand for dopamine D(3) receptors. I. In vitro characterization.
|
Synapse
|
2009
|
1.05
|
|
33
|
The c.-237_236GA>TT THAP1 sequence variant does not increase risk for primary dystonia.
|
Mov Disord
|
2011
|
1.04
|
|
34
|
Podokinetic after-rotation in Parkinson disease.
|
Brain Res
|
2006
|
1.04
|
|
35
|
Evidence that common variation in NEDD9 is associated with susceptibility to late-onset Alzheimer's and Parkinson's disease.
|
Hum Mol Genet
|
2007
|
1.03
|
|
36
|
Radiosynthesis and in vivo evaluation of [11C]MP-10 as a PET probe for imaging PDE10A in rodent and non-human primate brain.
|
Bioorg Med Chem
|
2011
|
1.03
|
|
37
|
A kinematic and electromyographic analysis of turning in people with Parkinson disease.
|
Neurorehabil Neural Repair
|
2008
|
1.02
|
|
38
|
Characterization of extrastriatal D2 in vivo specific binding of [¹⁸F](N-methyl)benperidol using PET.
|
Synapse
|
2012
|
1.01
|
|
39
|
Binding of the radioligand SIL23 to α-synuclein fibrils in Parkinson disease brain tissue establishes feasibility and screening approaches for developing a Parkinson disease imaging agent.
|
PLoS One
|
2013
|
1.00
|
|
40
|
Validation of a fiducial-based atlas localization method for deep brain stimulation contacts in the area of the subthalamic nucleus.
|
J Neurosci Methods
|
2007
|
0.99
|
|
41
|
Atlas template images for nonhuman primate neuroimaging: baboon and macaque.
|
Methods Enzymol
|
2004
|
0.99
|
|
42
|
Unilateral subthalamic nucleus stimulation has a measurable ipsilateral effect on rigidity and bradykinesia in Parkinson disease.
|
Exp Neurol
|
2008
|
0.98
|
|
43
|
Different effects of unilateral versus bilateral subthalamic nucleus stimulation on walking and reaching in Parkinson's disease.
|
Mov Disord
|
2003
|
0.98
|
|
44
|
Safety and efficacy of subthalamic nucleus deep brain stimulation performed with limited intraoperative mapping for treatment of Parkinson's disease.
|
Neurosurgery
|
2007
|
0.98
|
|
45
|
Novel haplotypes in 17q21 are associated with progressive supranuclear palsy.
|
Ann Neurol
|
2004
|
0.97
|
|
46
|
No differential regulation of dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) binding in a primate model of Parkinson disease.
|
PLoS One
|
2012
|
0.96
|
|
47
|
Decreased striatal dopamine receptor binding in primary focal dystonia: a D2 or D3 defect?
|
Mov Disord
|
2010
|
0.96
|
|
48
|
Validation of nigrostriatal positron emission tomography measures: critical limits.
|
Ann Neurol
|
2013
|
0.95
|
|
49
|
Dopamine D1, D2, D3 receptors, vesicular monoamine transporter type-2 (VMAT2) and dopamine transporter (DAT) densities in aged human brain.
|
PLoS One
|
2012
|
0.95
|
|
50
|
Motor asymmetry and substantia nigra volume are related to spatial delayed response performance in Parkinson disease.
|
Brain Cogn
|
2007
|
0.95
|
|
51
|
Levodopa challenge neuroimaging of levodopa-related mood fluctuations in Parkinson's disease.
|
Neuropsychopharmacology
|
2005
|
0.93
|
|
52
|
Effects of thalamic stimulation frequency on intention and postural tremor.
|
Exp Neurol
|
2007
|
0.93
|
|
53
|
Modified high-performance liquid chromatography with electrochemical detection method for plasma measurement of levodopa, 3-O-methyldopa, dopamine, carbidopa and 3,4-dihydroxyphenyl acetic acid.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2006
|
0.93
|
|
54
|
A quantitative study of α-synuclein pathology in fifteen cases of dementia associated with Parkinson disease.
|
J Neural Transm (Vienna)
|
2013
|
0.93
|
|
55
|
[18F]FDOPA PET as an endophenotype for Parkinson's Disease linkage studies.
|
Am J Med Genet B Neuropsychiatr Genet
|
2006
|
0.92
|
|
56
|
Endogenous dopamine (DA) competes with the binding of a radiolabeled D₃ receptor partial agonist in vivo: a positron emission tomography study.
|
Synapse
|
2011
|
0.92
|
|
57
|
Cerebral mitochondrial metabolism in early Parkinson's disease.
|
J Cereb Blood Flow Metab
|
2008
|
0.92
|
|
58
|
Replication of association between ELAVL4 and Parkinson disease: the GenePD study.
|
Hum Genet
|
2008
|
0.91
|
|
59
|
Postural tremor suppression is dependent on thalamic stimulation frequency.
|
Mov Disord
|
2006
|
0.91
|
|
60
|
A rapid method for mass screening for parkinsonism.
|
Neurotoxicology
|
2006
|
0.90
|
|
61
|
Parkinson's disease and apolipoprotein E: possible association with dementia but not age at onset.
|
Genomics
|
2002
|
0.90
|
|
62
|
Mood response to deep brain stimulation of the subthalamic nucleus in Parkinson's disease.
|
J Neuropsychiatry Clin Neurosci
|
2012
|
0.90
|
|
63
|
Low nigrostriatal reserve for motor parkinsonism in nonhuman primates.
|
Exp Neurol
|
2012
|
0.89
|
|
64
|
Asymmetric regional cerebral blood flow in sedated baboons measured by positron emission tomography (PET).
|
Am J Phys Anthropol
|
2003
|
0.89
|
|
65
|
Disparities in deep brain stimulation surgery among insured elders with Parkinson disease.
|
Neurology
|
2013
|
0.89
|
|
66
|
Heteroaromatic and aniline derivatives of piperidines as potent ligands for vesicular acetylcholine transporter.
|
J Med Chem
|
2013
|
0.88
|
|
67
|
Validation of midbrain positron emission tomography measures for nigrostriatal neurons in macaques.
|
Ann Neurol
|
2013
|
0.86
|
|
68
|
Functional anatomy of subthalamic nucleus stimulation in Parkinson disease.
|
Ann Neurol
|
2014
|
0.86
|
|
69
|
Normal platelet mitochondrial complex I activity in Huntington's disease.
|
Neurobiol Dis
|
2007
|
0.84
|
|
70
|
Radiation dosimetry of N-([11C]methyl)benperidol as determined by whole-body PET imaging of primates.
|
Eur J Nucl Med Mol Imaging
|
2007
|
0.84
|
|
71
|
Clinical features and comorbidity of mood fluctuations in Parkinson's disease.
|
J Neuropsychiatry Clin Neurosci
|
2002
|
0.83
|
|
72
|
In vitro and in vivo characterization of two C-11-labeled pet tracers for vesicular acetylcholine transporter.
|
Mol Imaging Biol
|
2014
|
0.83
|
|
73
|
To scan or not to scan: DaT is the question.
|
Neurology
|
2012
|
0.83
|
|
74
|
Functional changes in brain activity during acquisition and practice of movement sequences.
|
Motor Control
|
2004
|
0.82
|
|
75
|
A population-based study of parkinsonism in an Amish community.
|
Neuroepidemiology
|
2009
|
0.82
|
|
76
|
Platelet mitochondrial complex I and I+III activities do not correlate with cerebral mitochondrial oxidative metabolism.
|
J Cereb Blood Flow Metab
|
2010
|
0.82
|
|
77
|
Syntheses and radiosyntheses of two carbon-11 labeled potent and selective radioligands for imaging vesicular acetylcholine transporter.
|
Mol Imaging Biol
|
2014
|
0.81
|
|
78
|
Validation of the reference tissue model for estimation of dopaminergic D2-like receptor binding with [18F](N-methyl)benperidol in humans.
|
Nucl Med Biol
|
2008
|
0.81
|
|
79
|
Cognitive-pharmacologic functional magnetic resonance imaging in tourette syndrome: a pilot study.
|
Biol Psychiatry
|
2004
|
0.81
|
|
80
|
Effects of pallidotomy and levodopa on walking and reaching movements in Parkinson's disease.
|
Mov Disord
|
2003
|
0.81
|
|
81
|
Reduced uptake of FDOPA PET in end-stage liver disease with elevated manganese levels.
|
Arch Neurol
|
2012
|
0.81
|
|
82
|
Metabolic control of resting hemispheric cerebral blood flow is oxidative, not glycolytic.
|
J Cereb Blood Flow Metab
|
2011
|
0.80
|
|
83
|
LRRK2 gene G2019S mutation and SNPs [haplotypes] in subtypes of Parkinson's disease.
|
Parkinsonism Relat Disord
|
2008
|
0.80
|
|
84
|
MRI measures predict progressive supranuclear palsy: clinically useful?
|
Neurology
|
2011
|
0.79
|
|
85
|
Prevalence of parkin gene mutations and variations in idiopathic Parkinson's disease.
|
Parkinsonism Relat Disord
|
2005
|
0.79
|
|
86
|
Rapid intravenous loading of levodopa for human research: clinical results.
|
J Neurosci Methods
|
2003
|
0.79
|
|
87
|
Positron emission tomography imaging of dopamine D2 receptors using a highly selective radiolabeled D2 receptor partial agonist.
|
Neuroimage
|
2013
|
0.78
|
|
88
|
Association of a variation in the promoter region of the brain-derived neurotrophic factor gene with familial Parkinson's disease.
|
Parkinsonism Relat Disord
|
2004
|
0.78
|
|
89
|
Writer's cramp: questions of causation.
|
Neurology
|
2007
|
0.78
|
|
90
|
Perception of active and passive turning in Parkinson disease.
|
Neurorehabil Neural Repair
|
2007
|
0.77
|
|
91
|
Striatal dopamine D1-like receptor binding is unchanged in primary focal dystonia.
|
Mov Disord
|
2013
|
0.77
|
|
92
|
Botulinum toxin B reduces sialorrhea in parkinsonism.
|
Mov Disord
|
2003
|
0.77
|
|
93
|
Blind men and blinking elephants.
|
Neurology
|
2003
|
0.77
|
|
94
|
Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024).
|
Mov Disord
|
2002
|
0.77
|
|
95
|
Focal dystonias of the hand and upper extremity.
|
J Hand Surg Am
|
2008
|
0.76
|
|
96
|
Novel human pathological mutations. Gene symbol: THAP1. Disease: dystonia 6.
|
Hum Genet
|
2010
|
0.76
|
|
97
|
Enhancement of rigidity in Parkinson's disease with activation.
|
Mov Disord
|
2007
|
0.76
|
|
98
|
Reply: Levodopa increases functional connectivity in the cerebellum and brainstem in Parkinson's disease.
|
Brain
|
2013
|
0.76
|
|
99
|
Correction: Insulin, Central Dopamine D2 Receptors, and Monetary Reward Discounting in Obesity.
|
PLoS One
|
2016
|
0.75
|
|
100
|
Expert testimony at the Food and Drug Administration: who wants the truth?
|
Narrat Inq Bioeth
|
2011
|
0.75
|
|
101
|
Sex, drugs and Parkinson's disease.
|
Brain
|
2013
|
0.75
|
|
102
|
Carboxyfullerene neuroprotection postinjury in Parkinsonian nonhuman primates.
|
Ann Neurol
|
2014
|
0.75
|
|
103
|
Levodopa-responsive hemiparkinsonism secondary to cystic expansion from a coiled cerebral aneurysm.
|
J Neuroimaging
|
2014
|
0.75
|
|
104
|
Pharmacologic characterizations of a P2X7 receptor-specific radioligand, [11C]GSK1482160 for neuroinflammatory response.
|
Nucl Med Commun
|
2017
|
0.75
|
|
105
|
Vocal exercise versus voice rest following botulinum toxin injections: a randomized crossover trial.
|
Ann Otol Rhinol Laryngol
|
2009
|
0.75
|
|
106
|
Novel human pathological mutations. Gene symbol: THAP1. Disease: dystonia 6.
|
Hum Genet
|
2010
|
0.75
|
|
107
|
Synthesis, resolution, and in vitro evaluation of three vesicular acetylcholine transporter ligands and evaluation of the lead fluorine-18 radioligand in a nonhuman primate.
|
Org Biomol Chem
|
2017
|
0.75
|
|
108
|
Novel human pathological mutations. Gene symbol: THAP1. Disease: dystonia 6.
|
Hum Genet
|
2010
|
0.75
|
|
109
|
Novel human pathological mutations. Gene symbol: THAP1. Disease: dystonia 6.
|
Hum Genet
|
2010
|
0.75
|
|
110
|
Novel human pathological mutations. Gene symbol: THAP1. Disease: dystonia 6.
|
Hum Genet
|
2010
|
0.75
|